Comparative Pharmacology
Head-to-head clinical analysis: JANUMET XR versus SITAGLIPTIN METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANUMET XR versus SITAGLIPTIN METFORMIN HYDROCHLORIDE.
JANUMET XR vs SITAGLIPTIN; METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JANUMET XR is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases active incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Sitagliptin is a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin is a biguanide that decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity via AMP-kinase activation.
One tablet orally once daily, with evening meal; initial dose based on patient's current sitagliptin and metformin doses, or new patients: starting dose 50 mg sitagliptin/500 mg metformin XR; maximum dose 100 mg sitagliptin/2000 mg metformin XR per day.
1 tablet orally twice daily; each tablet contains sitagliptin 50 mg and metformin hydrochloride 500 mg, 850 mg, or 1000 mg; maximum dose: sitagliptin 100 mg/day, metformin 2000 mg/day.
None Documented
None Documented
Sitagliptin: terminal half-life ~12.4 hours, allowing once-daily dosing. Metformin: terminal half-life ~6.2 hours in plasma, increased to ~17.6 hours in renal impairment.
Sitagliptin: terminal half-life 12.4 hours (healthy), prolonged in renal impairment (up to 28–39 hours in severe impairment). Metformin: terminal half-life 4–8.7 hours (healthy), prolonged in renal impairment (up to 17.6 hours in moderate impairment).
Sitagliptin: ~79% excreted unchanged in urine via renal tubular secretion (active secretion) and glomerular filtration; ~13% undergoes hepatic metabolism; ~1% excreted in feces. Metformin: ~90% excreted unchanged in urine via active tubular secretion.
Sitagliptin: 79% excreted unchanged in urine via renal tubular secretion and glomerular filtration; 13% metabolized with 4% excreted in feces. Metformin: 90% excreted unchanged in urine via glomerular filtration and tubular secretion; <5% in feces.
Category C
Category A/B
DPP-4 Inhibitor/Biguanide Combination
DPP-4 Inhibitor